Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin

Who is this study for? Adult patients with treatment-naïve Unresected Laynx, Oropharynx, Hypopharynx, Oral Cavity, Head and Neck Squamous Cell Carcinoma
Status: Active, not recruiting
Location: See all (256) locations...
Intervention Type: Other, Biological, Radiation
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

This phase II/III trial studies how well radiation therapy works with durvalumab or cetuximab in treating patients with head and neck cancer that has spread to a local and/or regional area of the body who cannot take cisplatin. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. It is not known if radiation therapy with durvalumab will work better than the usual therapy of radiation therapy with cetuximab in treating patients with head and neck cancer.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No
View:

• PRIOR TO STEP 1 REGISTRATION INCLUSION CRITERIA

• Patients must have pathologically confirmed, previously untreated, unresected squamous cell carcinoma of the larynx, hypopharynx, oropharynx, oral cavity, or carcinoma of unknown head/neck primary prior to step 1 registration; submission of hematoxylin and eosin (H&E) stained slides and formalin-fixed and paraffin-embedded (FFPE) tissue block (or punch biopsy of FFPE block) to the biospecimen bank at University of California, San Francisco (UCSF) for central review for oropharyngeal and unknown primaries and for p16 analysis for all other non-oropharyngeal primaries is mandatory for all patients; investigators should check with their pathology department regarding release of biospecimens before approaching patients about participation in the trial; for oropharyngeal and unknown primaries, submission of H&E and p16 stained slides (with the required block for PD-L1) to the biospecimen bank at UCSF for central review is also required prior to step 2 registration

• Note: fine needle aspirates (FNA) samples are not acceptable since they do not provide enough material for PD-L1 and p16 testing; however, if a cell block derived from the FNA is available, it is allowable if there are sufficient cells present in the block for PD-L1 testing; Dr. Jordan will determine this upon receipt; for sites submitting FNA cell blocks for ALL patients they must do so within 7-10 business days from registering the patient; sites must confirm with their cytology/pathology labs to make sure they can provide the required material as the bank must be able to retain these samples for the mandatory testing

• Patients must have locoregionally advanced head and neck squamous cell carcinoma (HNSCC)

• For p16-positive oropharyngeal/unknown primaries, American Joint Committee on Cancer [AJCC] 8th edition stage III and selected stage I-II based on smoking status in pack-years

• For laryngeal, hypopharyngeal, and oral cavity primaries and p16-negative oropharyngeal/unknown primaries, AJCC 8th edition stage III-IVB

• Based on the following minimum diagnostic workup within 60 days prior to step 1 registration:

• General history and physical examination by a radiation oncologist or medical oncologist or ear, nose and throat (ENT) or head & neck surgeon

• For larynx, hypopharynx, and base of tongue primaries, a laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure) is required, unless the patient cannot tolerate or refuses

• Imaging of the head and neck with a neck CT or magnetic resonance imaging (MRI) (with contrast, unless contraindicated) or PET/CT; note that the CT portion of the PET/CT must be of diagnostic quality, including contrast administration unless contraindicated. If the CT portion of the PET/CT study is low-dose (non-diagnostic), then an additional CT or MRI study with contrast (unless contraindicated) is required

• Chest imaging: chest CT with and without contrast (unless contraindicated) or PET/CT

• Patients must have a contraindication to cisplatin as defined in the following bullet points; sites must complete the online tool at comogram.org prior to step 1 registration to determine if the patient is eligible; the scores must be recorded on a case report form (CRF)

• Age >= 70 with moderate to severe comorbidity or vulnerability to cisplatin, defined as having one or more of the following conditions within 30 days prior to step 1 registration:

• Modified Charlson Comorbidity Index >= 1

• Adult Comorbidity Evaluation (ACE)-27 Index >= 1

• Generalized Competing Event Model for Cancer Risk (GCE) omega PFS score < 0.80

• Geriatric screening (G-8) score =< 14

• Cancer and Aging Research Group (CARG) toxicity score >= 30%

• Cumulative Illness Rating scale for Geriatrics (CIRS-G) score >= 4 OR

• Age < 70 with severe comorbidity or vulnerability to cisplatin, defined as having two or more of the following conditions within 30 days prior to step 1 registration

• Modified Charlson Comorbidity Index >= 1

• ACE-27 Index >= 1

• GCE omega PFS-score < 0.80

• G-8 score =< 14

• CARG Toxicity score >= 30%

• CIRS-G score >= 4 OR

• Age >= 18 with an absolute or relative contraindication to cisplatin, defined as one or more of the following within 30 days prior to step 1 registration:

• Creatinine clearance (CC) > 30 and < 60 cc/min; for this calculation, use the Cockcroft-Gault formula

• Zubrod performance status 2 prior to step 1 registration

• Pre-existing peripheral neuropathy grade >= 1

• History of hearing loss, defined as either:

• Existing need of a hearing aid OR

• >= 25 decibel shift over 2 contiguous frequencies on a pretreatment hearing test as clinically indicated

• Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 (within 14 days prior to step 1 registration)

• Platelets >= 100,000 cells/mm^3 (within 14 days prior to step 1 registration)

• Hemoglobin >= 9.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 9.0 g/dl is acceptable) (within 14 days prior to step 1 registration)

• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 times institutional upper limit of normal (within 14 days prior to step 1 registration)

• Serum bilirubin =< 1.5 x institutional upper limit of normal (within 14 days prior to step 1 registration)

• Measured creatinine clearance (CL) > 30 mL/min or calculated creatinine CL > 30 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance (within 14 days prior to step 1 registration)

• For women of childbearing potential, a negative serum or urine pregnancy test within 14 days prior to step 1 registration; Note: women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause; the following age-specific requirements apply:

• Women < 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy)

• Women >= 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses > 1 year ago, had chemotherapy-induced menopause with last menses > 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)

• The patient or a legally authorized representative must provide study-specific informed consent prior to step 1 registration

• PRIOR TO STEP 2 REGISTRATION INCLUSION CRITERIA

• For patients with oropharyngeal or unknown primaries: p16 determination by immunohistochemistry (defined as greater than 70% strong nuclear or nuclear and cytoplasmic staining of tumor cells), confirmed by central pathology review

• Note: for patients with oral cavity, laryngeal, and hypopharyngeal primaries, analysis of p16 status prior to step 2 registration/randomization is not required (p16 status will be analyzed centrally post-hoc); step 2 registration for these patients can be completed after step 1 registration

Locations
United States
Alabama
University of Alabama at Birmingham Cancer Center
Birmingham
University of South Alabama Mitchell Cancer Institute
Mobile
Arizona
Banner MD Anderson Cancer Center
Gilbert
CTCA at Western Regional Medical Center
Goodyear
Banner University Medical Center - Tucson
Tucson
University of Arizona Cancer Center-North Campus
Tucson
California
Kaiser Permanente-Deer Valley Medical Center
Antioch
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn
Alta Bates Summit Medical Center-Herrick Campus
Berkeley
City of Hope Comprehensive Cancer Center
Duarte
Kaiser Permanente Dublin
Dublin
Kaiser Permanente-Fremont
Fremont
Fresno Cancer Center
Fresno
Kaiser Permanente-Fresno
Fresno
UC San Diego Moores Cancer Center
La Jolla
Cedars Sinai Medical Center
Los Angeles
Kaiser Permanente-Modesto
Modesto
Kaiser Permanente Oakland-Broadway
Oakland
Kaiser Permanente-Oakland
Oakland
Stanford Cancer Institute Palo Alto
Palo Alto
VA Palo Alto Health Care System
Palo Alto
Kaiser Permanente-Rancho Cordova Cancer Center
Rancho Cordova
Kaiser Permanente-Richmond
Richmond
Rohnert Park Cancer Center
Rohnert Park
Kaiser Permanente-Roseville
Roseville
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville
The Permanente Medical Group-Roseville Radiation Oncology
Roseville
Kaiser Permanente Downtown Commons
Sacramento
Kaiser Permanente-South Sacramento
Sacramento
South Sacramento Cancer Center
Sacramento
Sutter Medical Center Sacramento
Sacramento
University of California Davis Comprehensive Cancer Center
Sacramento
Kaiser Permanente-San Francisco
San Francisco
UCSF Medical Center-Mission Bay
San Francisco
UCSF Medical Center-Mount Zion
San Francisco
Kaiser Permanente-Santa Teresa-San Jose
San Jose
Kaiser Permanente San Leandro
San Leandro
Kaiser San Rafael-Gallinas
San Rafael
Kaiser Permanente Medical Center - Santa Clara
Santa Clara
Kaiser Permanente-Santa Rosa
Santa Rosa
City of Hope South Pasadena
South Pasadena
Kaiser Permanente Cancer Treatment Center
South San Francisco
Kaiser Permanente-South San Francisco
South San Francisco
Kaiser Permanente-Stockton
Stockton
Torrance Memorial Medical Center
Torrance
Torrance Memorial Physician Network - Cancer Care
Torrance
Gene Upshaw Memorial Tahoe Forest Cancer Center
Truckee
Kaiser Permanente Medical Center-Vacaville
Vacaville
Kaiser Permanente-Vallejo
Vallejo
Kaiser Permanente-Walnut Creek
Walnut Creek
Colorado
University of Colorado Hospital
Aurora
Memorial Hospital North
Colorado Springs
Penrose-Saint Francis Healthcare
Colorado Springs
UCHealth Memorial Hospital Central
Colorado Springs
Poudre Valley Hospital
Fort Collins
McKee Medical Center
Loveland
Connecticut
Smilow Cancer Hospital-Hamden Care Center
Hamden
Yale University
New Haven
Smilow Cancer Hospital Care Center-Trumbull
Trumbull
Smilow Cancer Hospital Care Center - Waterford
Waterford
Delaware
Beebe South Coastal Health Campus
Frankford
Helen F Graham Cancer Center
Newark
Beebe Health Campus
Rehoboth Beach
Florida
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach
Baptist MD Anderson Cancer Center
Jacksonville
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami
Moffitt Cancer Center
Tampa
Georgia
Emory University Hospital Midtown
Atlanta
Emory University Hospital/Winship Cancer Institute
Atlanta
Grady Health System
Atlanta
Augusta University Medical Center
Augusta
Hawaii
Hawaii Cancer Care Inc - Waterfront Plaza
Honolulu
Queen's Medical Center
Honolulu
The Cancer Center of Hawaii-Liliha
Honolulu
Iowa
Mercy Cancer Center-West Lakes
Clive
Iowa Methodist Medical Center
Des Moines
Mercy Medical Center - Des Moines
Des Moines
Idaho
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell
Saint Alphonsus Medical Center-Nampa
Nampa
Illinois
John H Stroger Jr Hospital of Cook County
Chicago
Northwestern University
Chicago
Rush University Medical Center
Chicago
University of Illinois
Chicago
Decatur Memorial Hospital
Decatur
Crossroads Cancer Center
Effingham
Western Illinois Cancer Treatment Center
Galesburg
Methodist Medical Center of Illinois
Peoria
OSF Saint Francis Medical Center
Peoria
Memorial Medical Center
Springfield
Carle Cancer Center
Urbana
Indiana
IU Health North Hospital
Carmel
Parkview Hospital Randallia
Fort Wayne
Parkview Regional Medical Center
Fort Wayne
Community Cancer Center East
Indianapolis
Community Cancer Center North
Indianapolis
Community Cancer Center South
Indianapolis
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis
Sidney and Lois Eskenazi Hospital
Indianapolis
Kansas
University of Kansas Cancer Center
Kansas City
University of Kansas Cancer Center-Overland Park
Overland Park
Salina Regional Health Center
Salina
University of Kansas Hospital-Westwood Cancer Center
Westwood
Ascension Via Christi Hospitals Wichita
Wichita
Kentucky
University of Kentucky/Markey Cancer Center
Lexington
Norton Brownsboro Hospital and Medical Campus
Louisville
Norton Hospital Pavilion and Medical Campus
Louisville
The James Graham Brown Cancer Center at University of Louisville
Louisville
Louisiana
East Jefferson General Hospital
Metairie
Massachusetts
Boston Medical Center
Boston
Lahey Hospital and Medical Center
Burlington
Maryland
Greater Baltimore Medical Center
Baltimore
Michigan
Saint Joseph Mercy Hospital
Ann Arbor
University of Michigan Comprehensive Cancer Center
Ann Arbor
McLaren Cancer Institute-Bay City
Bay City
Saint Joseph Mercy Brighton
Brighton
Henry Ford Cancer Institute-Downriver
Brownstown
Saint Joseph Mercy Canton
Canton
Saint Joseph Mercy Chelsea
Chelsea
McLaren Cancer Institute-Clarkston
Clarkston
Henry Ford Macomb Hospital-Clinton Township
Clinton Township
Henry Ford Hospital
Detroit
Wayne State University/Karmanos Cancer Institute
Detroit
Weisberg Cancer Treatment Center
Farmington Hills
McLaren Cancer Institute-Flint
Flint
Singh and Arora Hematology Oncology PC
Flint
Allegiance Health
Jackson
Karmanos Cancer Institute at McLaren Greater Lansing
Lansing
Mid-Michigan Physicians-Lansing
Lansing
Sparrow Hospital
Lansing
McLaren Cancer Institute-Lapeer Region
Lapeer
McLaren Cancer Institute-Macomb
Mount Clemens
McLaren Cancer Institute-Northern Michigan
Petoskey
McLaren-Port Huron
Port Huron
Ascension Saint Mary's Hospital
Saginaw
Henry Ford West Bloomfield Hospital
West Bloomfield
Minnesota
Sanford Joe Lueken Cancer Center
Bemidji
Fairview Ridges Hospital
Burnsville
Miller-Dwan Hospital
Duluth
Fairview Southdale Hospital
Edina
Unity Hospital
Fridley
Hennepin County Medical Center
Minneapolis
Mayo Clinic in Rochester
Rochester
Coborn Cancer Center at Saint Cloud Hospital
Saint Cloud
Regions Hospital
Saint Paul
Missouri
Saint Francis Medical Center
Cape Girardeau
Siteman Cancer Center at West County Hospital
Creve Coeur
Mercy Hospital Saint Louis
Saint Louis
Washington University School of Medicine
Saint Louis
Siteman Cancer Center at Saint Peters Hospital
Saint Peters
Montana
Billings Clinic Cancer Center
Billings
Kalispell Regional Medical Center
Kalispell
North Carolina
Atrium Health Stanly/LCI-Albemarle
Albemarle
UNC Lineberger Comprehensive Cancer Center
Chapel Hill
Atrium Health Pineville/LCI-Pineville
Charlotte
Carolinas Medical Center/Levine Cancer Institute
Charlotte
Atrium Health Cabarrus/LCI-Concord
Concord
Margaret R Pardee Memorial Hospital
Hendersonville
Atrium Health Union/LCI-Union
Monroe
North Dakota
Sanford Roger Maris Cancer Center
Fargo
Nebraska
CHI Health Saint Francis
Grand Island
New Hampshire
Dartmouth Hitchcock Medical Center
Lebanon
New Jersey
Memorial Sloan Kettering Basking Ridge
Basking Ridge
Hackensack University Medical Center
Hackensack
Memorial Sloan Kettering Monmouth
Middletown
Memorial Sloan Kettering Bergen
Montvale
New Mexico
New Mexico Oncology Hematology Consultants
Albuquerque
University of New Mexico Cancer Center
Albuquerque
New York
James J Peters VA Medical Center
Bronx
Montefiore Medical Center - Moses Campus
Bronx
Roswell Park Cancer Institute
Buffalo
Memorial Sloan Kettering Commack
Commack
Memorial Sloan Kettering Westchester
Harrison
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York
Memorial Sloan Kettering Cancer Center
New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York
University of Rochester
Rochester
Stony Brook University Medical Center
Stony Brook
State University of New York Upstate Medical University
Syracuse
Memorial Sloan Kettering Nassau
Uniondale
Ohio
Aultman Health Foundation
Canton
Cleveland Clinic Mercy Hospital
Canton
Geauga Hospital
Chardon
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati
Case Western Reserve University
Cleveland
Cleveland Clinic Foundation
Cleveland
MetroHealth Medical Center
Cleveland
Ohio State University Comprehensive Cancer Center
Columbus
Cleveland Clinic Cancer Center Mansfield
Mansfield
UH Seidman Cancer Center at Lake Health Mentor Campus
Mentor
North Coast Cancer Care
Sandusky
ProMedica Flower Hospital
Sylvania
University of Cincinnati Cancer Center-West Chester
West Chester
UHHS-Westlake Medical Center
Westlake
Cleveland Clinic Wooster Family Health and Surgery Center
Wooster
Oklahoma
University of Oklahoma Health Sciences Center
Oklahoma City
Oregon
Good Samaritan Hospital
Corvallis
Kaiser Permanente Northwest
Portland
Providence Portland Medical Center
Portland
Providence Saint Vincent Medical Center
Portland
Pennsylvania
Jefferson Abington Hospital
Abington
Crozer-Keystone Regional Cancer Center at Broomall
Broomall
Christiana Care Health System-Concord Health Center
Chadds Ford
Geisinger Medical Center
Danville
Penn State Milton S Hershey Medical Center
Hershey
Geisinger Medical Oncology-Lewisburg
Lewisburg
Lewistown Hospital
Lewistown
Forbes Hospital
Monroeville
Fox Chase Cancer Center
Philadelphia
Temple University Hospital
Philadelphia
Allegheny General Hospital
Pittsburgh
UPMC-Shadyside Hospital
Pittsburgh
Guthrie Medical Group PC-Robert Packer Hospital
Sayre
Reading Hospital
West Reading
Wexford Health and Wellness Pavilion
Wexford
Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-barre
Asplundh Cancer Pavilion
Willow Grove
South Carolina
Medical University of South Carolina
Charleston
Gibbs Cancer Center-Pelham
Greer
Rock Hill Radiation Therapy Center
Rock Hill
Spartanburg Medical Center
Spartanburg
South Dakota
Avera Cancer Institute
Sioux Falls
Sanford USD Medical Center - Sioux Falls
Sioux Falls
Texas
M D Anderson Cancer Center
Houston
Virginia
University of Virginia Cancer Center
Charlottesville
Sentara Norfolk General Hospital
Norfolk
VCU Massey Cancer Center at Stony Point
Richmond
Virginia Commonwealth University/Massey Cancer Center
Richmond
Vermont
Norris Cotton Cancer Center-North
Saint Johnsbury
Washington
University of Washington Medical Center - Montlake
Seattle
Wisconsin
Langlade Hospital and Cancer Center
Antigo
Aurora BayCare Medical Center
Green Bay
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay
Saint Vincent Hospital Cancer Center Green Bay
Green Bay
UW Cancer Center Johnson Creek
Johnson Creek
Aurora Cancer Care-Kenosha South
Kenosha
Gundersen Lutheran Medical Center
La Crosse
University of Wisconsin Carbone Cancer Center
Madison
Aurora Bay Area Medical Group-Marinette
Marinette
Froedtert Menomonee Falls Hospital
Menomonee Falls
Aurora Saint Luke's Medical Center
Milwaukee
Medical College of Wisconsin
Milwaukee
Zablocki Veterans Administration Medical Center
Milwaukee
ProHealth D N Greenwald Center
Mukwonago
ProHealth Oconomowoc Memorial Hospital
Oconomowoc
Vince Lombardi Cancer Clinic-Sheboygan
Sheboygan
Aurora Medical Center in Summit
Summit
UW Cancer Center at ProHealth Care
Waukesha
Aspirus Regional Cancer Center
Wausau
Aurora West Allis Medical Center
West Allis
Froedtert West Bend Hospital/Kraemer Cancer Center
West Bend
West Virginia
West Virginia University Healthcare
Morgantown
Other Locations
Canada
London Regional Cancer Program
London
The Research Institute of the McGill University Health Centre (MUHC)
Montreal
Allan Blair Cancer Centre
Regina
University Health Network-Princess Margaret Hospital
Toronto
Time Frame
Start Date: December 12, 2017
Estimated Completion Date: December 31, 2025
Participants
Target number of participants: 493
Treatments
Active Comparator: Arm I (cetuximab, radiation therapy)
Patients receive cetuximab IV weekly over 60-120 minutes. Treatment repeats every week for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Beginning 5-7 days after first cetuximab dose, patients undergo IMRT 5 fractions per week for up to 7 weeks.
Experimental: Arm II (durvalumab, radiation therapy)
Patients receive durvalumab IV over 60 minutes every 4 weeks. Treatment repeats every 4 weeks for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Beginning week 2, patients undergo IMRT 5 fractions per week for up to 7 weeks.
Authors
Randall J. Kimple, Willard G. Andrews, Yeun-Hee A. Park, Sharon A. Spencer, Michael A. Samuels, Robert J. Behrens, Minh T. Truong, Matthew L. Ryan, Jonathan J. Beitler, Larisa Greenberg, Bryan A. Faller, Diane M. Hershock, Marcelo R. Bonomi, Abderrahim Khomani, Min Yao, Shruti Trehan, Amit K. Bhatt, David I. Rosenthal, Preston D. Steen, Philip A. Lowry, Yujie Zhao, Julie E. Bauman, Paul W. Sperduto, Yuhchyau Chen, Jay W. Carlson, Sachin G. Pai, Vamsi K. Vasireddy, Kartik M. Mani, Chiaojung J. Tsai, Neilayan Sen, Mehmet S. Copur, Neal E. Dunlap, David J. Adelstein, Anand Mahadevan, Loren Mell, Sue S. Yom, Lawrence E. Feldman, Alan Tan, Anand K. Sharma, Helen J. Ross, David M. Hufnagel, Kevin P. Redmond, Timothy R. Wassenaar, Julie A. Kish, James E. Radford, Donald J. Jurgens, Anurag K. Singh, Ken Tatebe, Jessica L. Geiger, Thomas E. Lad, Zachary S. Zumsteg, Christopher U. Jones, Krishna C. Alluri, John M. Schallenkamp, Zujun Li, Gregory A. Masters, Paul L. Swiecicki, Keren Sturtz, Vishangi Dave, Matthen Mathew, Kiran Devisetty, Shyam S. Rao, Beth M. Beadle, Eleanor M. Walker, Sagus Sampath, Thomas J. Galloway, Siddhartha Padmanabha, Conor E. Steuer, Lynn J. Howie, Ellen L. Ziaja, Samir Narayan, Nicholas DiBella, Christina Henson, Seung S. Hahn, Benny J. Liem, Terrence P. Cescon, Elizabeth M. Gore, Nikhil P. Joshi, Jeffrey A. Forquer, Stuart J. Wong, Daniel R. Carrizosa, Harlan A. Pinto, Collin D. Driscoll, Salah M. Almokadem, Edwin F. Crandley, Francis P. Worden, Douglas R. Adkins, Jordan Kharofa, Samantha A. Seaward, Dan S. Zuckerman, Edward J. Walsh, Philip E. Schaner, Benjamin M. Solomon, Geoffrey A. Neuner, Sana D. Karam, Rafi Kabarriti, Cristina P. Rodriguez, Siddharth Sheth, James L. Wade, Benjamin T. Marchello, Gregory N. Gan, Victoria M. Villaflor, Varinder Kaur, Sandeep H. Mashru, Shih J. Wei, Bret E. Friday, Melissa R. Young, Aaron C. Spalding, Todd C. Tenenholz, Kaveh Zakeri, Richard L. Deming, Susanne M. Arnold, Sarah Y. Wang, Anterpreet S. Neki, Christopher S. Platta, J. S. Thompson, Sarah W. Gordon, Francis W. Nugent, Richard Y. Lee, Christopher Lominska, Katharine A. Price, George Shenouda, Sharad A. Ghamande, David A. Clump, Vinita Takiar, Aaron Hansen, Ayesha Bashir, Robert S. Alter, William Tse, Pavan S. Reddy, Greg Durm, Eric W. Winquist
Sponsors
Collaborators: Canadian Cancer Trials Group, NRG Oncology
Leads: National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov

Similar Clinical Trials